.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have discovered that IL-39 in Myasthenia Gravis (MG) serves as a potent indicator of disease severity. This novel cytokine, a member of the IL-12 family, appears to play a critical role in the immune-mediated pathology of the condition.
Moreover, a study conducted by Jia K and colleagues analyzed serum samples from 51 patients with acetylcholine receptor (AChR) antibody-positive MG. They compared these to 43 healthy controls to establish a baseline for comparison. The results showed that active MG patients had significantly higher IL-39 levels than healthy individuals.
Furthermore, the study found a strong positive correlation between IL-39 concentrations and clinical assessment tools like the MG-ADL score. Patients with more severe symptoms, categorized under higher MGFA classifications, consistently displayed elevated cytokine levels. Significantly, when patients achieved remission after immunotherapy, their IL-39 levels dropped sharply.
Consequently, this suggests that the cytokine could act as a longitudinal biomarker to monitor treatment efficacy in clinical settings. Overall, IL-39 offers high diagnostic accuracy, as shown by an area under the curve (AUC) of 0.922. Doctors may soon use this measurement to improve personalized care for MG patients.
IL-39 levels correlate with disease activity scores. Doctors can use these measurements to determine the severity of the condition and monitor how well a patient responds to immunotherapy.
Yes, research shows that patients with active MG have significantly higher serum IL-39 levels compared to healthy controls, with a high diagnostic accuracy rate.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Serum IL-39 shows promise as a new biomarker for Myasthenia Gravis, helping clinicians track disease activity and monitor response to immunotherapy....
7 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
